Review and Validation of Bayesian Dose‐Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients

Prospective evaluation of vancomycin pharmacokinetics in a heterogeneous critically ill population

(2018) R. Brigg Turner et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Hospitalized Patients With and Without Hemodialysis Have Markedly Different Vancomycin Pharmacokinetics

(2018) Vineet Goti et al.   THERAPEUTIC DRUG MONITORING

The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion

(2015) M. F. Waineo et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Innovative approaches to optimizing the delivery of vancomycin in individual patients

(2014) Manjunath P. Pai et al.   ADVANCED DRUG DELIVERY REVIEWS

Vancomycin Exposure in Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: How Much Is Enough?

(2014) Thomas P. Lodise et al.   CLINICAL INFECTIOUS DISEASES

Vancomycin Monitoring in Children Using Bayesian Estimation

(2014) Jennifer Le et al.   THERAPEUTIC DRUG MONITORING

Vancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia

(2013) Natasha E. Holmes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Are Vancomycin Trough Concentrations Adequate for Optimal Dosing?

(2013) Michael N. Neely et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Stewardship Program’s Retrospective Evaluation of Vancomycin AUC24/MIC and Time to Microbiological Clearance in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia and Osteomyelitis

(2013) Kristen M. Gawronski et al.   CLINICAL THERAPEUTICS

Is Peak Concentration Needed in Therapeutic Drug Monitoring of Vancomycin? A Pharmacokinetic-Pharmacodynamic Analysis in Patients with Methicillin-ResistantStaphylococcus aureusPneumonia

(2012) Yosuke Suzuki et al.   CHEMOTHERAPY

Evaluation of Once-Daily Vancomycin against Methicillin-Resistant Staphylococcus aureus in a Hollow-Fiber Infection Model

(2011) Anthony M. Nicasio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Vancomycin AUC24/MIC Ratio in Patients with Complicated Bacteremia and Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus and Its Association with Attributable Mortality during Hospitalization

(2011) Jack Brown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Vancomycin: We Can't Get There From Here

(2011) N. Patel et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children

(2011) Catherine Liu et al.   CLINICAL INFECTIOUS DISEASES

Relationship between Initial Vancomycin Concentration‐Time Profile and Nephrotoxicity among Hospitalized Patients

(2009) Thomas P. Lodise et al.   CLINICAL INFECTIOUS DISEASES

Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations

(2009) A. H. Thomson et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

(2008) M. Rybak et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy

(2008) P. R. Ingram et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY